Lorenzo De Marco

Dr. Lorenzo De Marco

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 December 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
LMLorenzo De Marco
Lorenzo De Marco
SDSilvia D’orso
Silvia D’orso
MPMarta Pirronello
Marta Pirronello
AVAlice Verdiani
Alice Verdiani
ATAndrea Termine
Andrea Termine
GBGiovanna Borsellino
Giovanna Borsellino
Importance: The emergence of the highly contagious Omicron variant of SARS-CoV-2 and the findings of a significantly reduced neutralizing potency of sera from convalescent or vaccinated individuals imposes the study of cellular immunity to predict the degree of immune protection to the yet again new coronavirus. Design: Prospective monocentric observational study. Setting: Conducted between December 20-21 at the Santa Lucia Foundation IRCCS. Participants: 61 volunteers (Mean age 41.62, range 21-62; 38F/23M) with different vaccination and SARS-CoV-2 infection backgrounds donated 15 ml of blood. Of these donors, one had recently completed chemotherapy, and one was undergoing treatment with monoclonal antibodies; the others reported no known health issue. Main Outcome(s) and Measure(s): The outcomes were the measurement of T cell reactivity to the mutated regions of the Spike protein of the Omicron SARS-CoV-2 variant and the assessment of remaining T cell immunity to the spike protein by stimulation with peptide libraries. Results: Lymphocytes from freshly drawn blood samples were isolated and immediately tested for reactivity to the Spike protein of SARS-CoV-2. T cell responses to peptides covering the mutated regions in the Omicron variant were decreased by over 47% compared to the same regions of the ancestral vaccine strain. However, overall reactivity to the peptide library of the full-length protein was largely maintained (estimated 83%). No significant differences in loss of immune recognition were identified between groups of donors with different vaccination and/or infection histories. Conclusions and Relevance: We conclude that despite the mutations in the Spike protein, the SARS-CoV-2 Omicron variant is nonetheless recognized by the cellular component of the immune system. It is reasonable to assume that protection from hospitalization and severe disease is maintained. Key Points: Question: Does the Omicron variant of SARS-CoV-2 escape cellular immunity? Findings: This observational study was performed on 61 vaccinated donors with established immunity to SARS-CoV-2. Cellular responses to the mutated regions of the Omicron Spike protein were detected in 80% of donors. The mutations reduced T cell recognition by 47% compared to the vaccine strain. Reactivity to the whole Spike protein, however, was present in 100% of donors, and the fraction of remaining immunity to SARS-CoV-2 was estimated to be 83%. Meaning: Cellular immunity to the Omicron variant is maintained despite the mutations in its Spike protein, and may thus confer protection from severe COVID-19 in vaccinated individuals.

12 November 2025 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
LMLorenzo De Marco
Lorenzo De Marco
EMElisa Micarelli
Elisa Micarelli
JPJoni Panula
Joni Panula
JNJussi Nikkola
Jussi Nikkola
LMLauri Moilanen
Lauri Moilanen
TSToni Seppälä
Toni Seppälä
Lynch syndrome is characterized by the development of microsatellite-instable cancers that share neoantigens, offering an opportunity for targeted immunotherapy. NOUS-209 is a heterologous prime-boost cancer vaccine in clinical development, employing viral vectors encoding 209 shared neoantigen peptides derived from frameshift mutations (FSM) commonly found in microsatellite-instable tumors. In this study, we investigated the presence and dynamics of NOUS-209 targeted FSMs in both primary and metachronous Lynch syndrome–associated cancers. Whole-exome sequencing was performed for 73 tumors, including 58 colorectal cancers and 15 urothelial cancers, from 58 individuals with confirmed Lynch syndrome. A median of 57 FSMs per colorectal cancer and 24 FSMs per urothelial cancer were observed, with similar FSM burdens in both primary and metachronous tumors. Analysis of nine matched primary–metachronous tumor pairs revealed evidence of immune editing: FSMs predicted to encode highly immunogenic neoepitopes were selectively lost in metachronous tumors, whereas those with lower predicted immunogenicity were retained. Importantly, all subsequent primary cancers acquired novel FSMs encoding neoantigens with strong predicted HLA-binding affinity, supporting the rationale for NOUS-209–mediated immune interception. These findings demonstrated that NOUS-209 FSMs are present in both colorectal cancers and urothelial cancers in Lynch syndrome, expanding the therapeutic potential of NOUS-209 beyond colorectal cancer. Moreover, the emergence of novel targetable FSMs in metachronous tumors suggests that NOUS-209 immunotherapy may be effective in the prevention of both primary and metachronous Lynch syndrome–associated cancers.

9 November 2023 in Vaccines
Verified
Journal Article
Open access
PDF file
SDSilvia D’orso
Silvia D’orso
MPMarta Pirronello
Marta Pirronello
AVAlice Verdiani
Alice Verdiani
ARAngelo Rossini
Angelo Rossini
GGGisella Guerrera
Gisella Guerrera
GBGiovanna Borsellino
Giovanna Borsellino
Breakthrough infections in SARS-CoV-2 vaccinated individuals are an ideal circumstance for the simultaneous exploration of both the vaccine-induced memory reaction to the spike (S) protein and the primary response to the membrane (M) and nucleocapsid (N) proteins generated by natural infection. We monitored 15 healthcare workers who had been vaccinated with two doses of Pfizer BioNTech BNT162b2 and were then later infected with the SARS-CoV-2 B.1.617.2. (Delta) variant, analysing the antiviral humoral and cellular immune responses. Natural infection determined an immediate and sharp rise in anti-RBD antibody titres and in the frequency of both S-specific antibody secreting cells (ASCs) and memory B lymphocytes. T cells responded promptly to infection by activating and expanding already at 2–5 days. S-specific memory and emerging M- and N-specific T cells both expressed high levels of activation markers and showed effector capacity with similar kinetics but with different magnitude. The results show that natural infection with SARS-CoV-2 in vaccinated individuals induces fully functional and rapidly expanding T and B lymphocytes in concert with the emergence of novel virus-specific T cells. This swift and punctual response also covers viral variants and captures a paradigmatic case of a healthy adaptive immune reaction to infection with a mutating virus.

18 June 2026 in Annals of Neurology
Verified
Journal Article
Open access
MPMarta Pirronello
Marta Pirronello
MPMario Picozza
Mario Picozza
GGGisella Guerrera
Gisella Guerrera
SCSilvia Corbisiero
Silvia Corbisiero
AMAndrea Misiti
Andrea Misiti
LBLuca Battistini
Luca Battistini
Objective: Multiple sclerosis (MS) is a chronic autoimmune disease where B cells play a central pathogenic role. Cladribine, an oral therapy, provides durable benefits by reshaping lymphocyte populations, yet its specific long‐term impact on distinct B‐cell subsets is not fully understood. This study aimed to define cladribine's longitudinal effects on B‐cell subsets and characterize their inflammatory properties. Methods: We conducted a 48‐month longitudinal study of 36 persons with relapsing–remitting MS treated with cladribine who had completed 2 annual treatment cycles, using high‐parameter flow cytometry to track B‐cell subset dynamics. In a parallel cross‐sectional analysis, B cells from 16 untreated patients and 16 healthy donors were profiled for polyfunctional cytokine production granulocyte‐macrophage colony stimulating factor (GM‐CSF), interleukin‐6 (IL‐6), tumor necrosis factor‐α (TNF‐α) and key surface markers. Results: Cladribine induced profound, sustained depletion of memory B cells, with marginal zone‐like (MZ‐like) cells showing the deepest and most persistent loss, alongside reconstitution of transitional and naïve populations. Functionally, MZ‐like B cells were the most potent polyfunctional producers of proinflammatory cytokines and immunoglobulin M (IgM), a capacity significantly enhanced in persons with MS compared to healthy donors, and expressed the highest levels of CD1c and CD1d, consistent with specialization in lipid antigen presentation. Interpretation: MZ‐like B cells are a dominant, polyfunctional inflammatory subset in MS, equipped for non‐canonical lipid antigen presentation and IgM secretion. They represent a preferential pharmacological target of cladribine. Sustained reduction of this pathogenic memory pool, followed by repopulation with less inflammatory B cells, offers a mechanistic basis for cladribine's durable clinical benefit and nominates MZ‐like cells as biomarkers of response and therapeutic targets. ANN NEUROL 2026

5 August 2025 in NAR Genomics and Bioinformatics
Verified
Journal Article
Open access
CPChiara Parrillo
Chiara Parrillo
MKMichele Kulesko
Michele Kulesko
FPFederica Persiani
Federica Persiani
LMLorenzo De Marco
Lorenzo De Marco
PPPaolo Petescia
Paolo Petescia
LGLuciano Giaco'
Luciano Giaco'
CBioPortal has established itself as a widely used platform for exploring and visualizing multidimensional cancer data. Additionally, users have the option to upload their own cancer study for a comprehensive experience. However, the uploading step can be challenging due to the numerous files required by the platform, as well as the meticulous review of genomic alterations that need to be included in the study. Therefore, there is an increasing need for efficient data management solutions to facilitate the creation of studies in cBioPortal and optimize user experience by streamlining research workflows. In this application note, we present Varan, an innovative data management tool developed to help users at the initial stage of cancer genomic studies' upload, enhancing the data preparation process. Varan addresses challenges related to data formatting, filtering variants based on annotation, metadata file creation, quality checks, and study versioning, thereby enabling researchers to shorten the preparation process time and have control over the type of data to be uploaded to cBioPortal. In conclusion, Varan significantly improves the efficiency and accuracy of preparing cancer genomic studies for cBioPortal, ultimately enhancing the user experience and advancing cancer research through streamlined data management.

2 April 2026
Verified
Other
Open access
LMLorenzo De Marco
Lorenzo De Marco
EMElisa Micarelli
Elisa Micarelli
JPJoni Panula
Joni Panula
JNJussi Nikkola
Jussi Nikkola
LMLauri Moilanen
Lauri Moilanen
TSToni Seppälä
Toni Seppälä
Overview of colorectal cancer and urothelial cancer cohorts. A and B, Bar plots showing the number of NOUS-209 FSMs detected in each sample of colorectal cancer and urothelial cancer cohorts. The median number of mutations is indicated by the blue dashed line (colorectal cancer = 57; urothelial cancer = 24). C, Venn diagram illustrating the overlap of NOUS-209 FSMs between colorectal cancer and urothelial cancer. D and E, Bar plots displaying the MSI scores in the colorectal cancer and urothelial cancer cohorts, respectively. The blue dashed line represents the recommended threshold of MSI score (20%) for classifying a sample as MSI. Lighter bars indicate samples classified as MSS. CRC, colorectal cancer; UC, urothelial cancer.